Company news

Biogen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

October 29, 2026

Q3 2026 Biogen Earnings Presentation

October 28, 2026

Biogen Reports Third Quarter 2026 Results

October 28, 2026

Biogen Canada Provides Update on CDA Draft Recommendation Supporting Expanded Public Reimbursement of SPINRAZA™ for Canadians with SMA

October 26, 2026

Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

October 19, 2026

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

October 2, 2026

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

September 17, 2026

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

September 16, 2026

LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

September 2, 2026

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

August 31, 2026

Veeva Vault CRM Selected by Biogen

August 25, 2026

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

August 24, 2026

LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease

August 24, 2026

Biogen Completes Acquisition of RayThera Inc.

August 6, 2026

Biogen Reports Second Quarter 2026 Results

July 29, 2026

Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

July 16, 2026

Biogen Appoints Michael J. Parini as Chief Legal Officer

July 15, 2026

Diranersen Results at AAIC Provide First Evidence That Targeting Tau May Slow Cognitive Decline, Signaling Momentum Toward Addressing the Full Pathobiology of Alzheimer's

July 14, 2026

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

July 14, 2026

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

July 14, 2026

Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease

July 14, 2026

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

July 13, 2026

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

July 12, 2026

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

June 29, 2026

Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

June 17, 2026

Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

June 5, 2026

Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy

June 3, 2026

Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses

June 3, 2026

Biogen Announces Webcast of Annual Meeting of Stockholders

May 28, 2026

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

May 21, 2026

The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer's Pathologies in Biogen's Phase 2 Tau Study

May 14, 2026

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

May 8, 2026

Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent

May 5, 2026

BIIB Q1 26 Earnings Presentation Final

April 29, 2026

Biogen Reports Q1 2026 Earnings

April 29, 2026

Q1 2026 Earnings Press Release Final

April 29, 2026

Biogen Reports First Quarter 2026 Results

April 29, 2026

TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region

April 20, 2026

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

April 20, 2026

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform

April 7, 2026

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

March 30, 2026

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

March 29, 2026

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

March 27, 2026

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

March 25, 2026

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

March 20, 2026

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

March 18, 2026

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

March 10, 2026

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

March 5, 2026

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

March 4, 2026

Biogen Announces Board Chair Transition

February 10, 2026

Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 53 decks. Every deck is listed under its year.